Fig. 3
From: AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
Comparison of cumulative HCC recurrence (%) in the early phase (within 1 year after DAA treatment) by post-treatment AFP ≥6.0 ng/mL (A). Cumulative HCC recurrence in the early phase is significantly higher in the high-AFP group than in the low-AFP group according to the log-rank test (p = 0.040). Comparison of cumulative HCC recurrence (%) in the late phase (more than 1 year after DAA treatment) by post-treatment eGFR ≤70 mL/min/1.73 m2 (B). Cumulative HCC recurrence in the late phase is significantly higher in the low-eGFR group than in the high-eGFR group according to the log-rank test (p = 0.008). Comparison of cumulative HCC recurrence (%) in the late phase in patients with post-treatment eGFR > 70 mL/min/1.73 m2 between groups with and without diabetes mellitus (DM) (C). Cumulative HCC recurrence in the late phase is significantly higher in the group with DM than in the group without DM according to the log-rank test (p = 0.019)